Nikoletta Nikolenko

A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)

Joseph P. Horrigan, Tiago Gomes, Mike Snape et al. · Pediatric Neurology · 2020 · 89 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +9

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study

Eline van Overbeeke, Rosanne Janssens, Chiara Whichello et al. · Frontiers in Pharmacology · 2019 · 76 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +17

The method of Poincaré normal forms in problems of integrability of equations of evolution type

Nikoletta Nikolenko · Russian Mathematical Surveys · 1986 · 46 citations

Natural Sciences, Mathematics, Differential Equations +13

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

Rosanne Janssens, Selena Russo, Eline van Overbeeke et al. · Patient · 2019 · 38 citations · Full text

Public Affairs, Health Care Management, Health Policy +17

Disease burden of myotonic dystrophy type 1

Erik Landfeldt, Nikoletta Nikolenko, Cecilia Jimenez‐Moreno et al. · Journal of Neurology · 2019 · 36 citations · Full text

Medicine, Internal Medicine, Neurology +9